Agilent Technologies Inc, an over $5.8-billion measurement company, expects the government sector in India to generate optimal revenues this calendar year, as compared with the pharma sector ?as the latter is facing the slowdown heat,? said Sanjeev Dhar, country head (sales - life sciences and chemical analysis group).
?Slowdown has cast a shadow on the pharma industry for plenty of reasons. However, the government investments continue to be very strong, especially in biotechnology, life sciences, food, safety and quality testing. In the past (till 2008), the revenue contribution from the pharma sector was about 70 percent and the rest from the government. This year it will be 50:50,? he said.
Agilent Technologies witnessed 27 percent of its revenues coming from Europe in 2008, while the
Dhar said the company would expand into the omics (comprehensive analysis of a specific layer in a cellular system) segment, CRO (contract research organisation), academia, government and other life sciences applications in the country.
Agilent on Tuesday launched its new gas chromatograph (GCs) in the Indian market. The product can be used to test volatile and non-volatile components in pharma substances, specialty chemicals, environmental and food, flavours and fragrances segments.
?We are targeting small and medium enterprises (SMEs), academia and government testing labs at the local district level to market this tailor-made equipment and we intend to garner a quarter of the business from the SME sector worldwide, of which a larger chunk will come from India,? he added.
Source: Business Standard
0 comments:
Post a Comment